Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 21NET 2Endocrine 2Sarcoma 1Other neoplasm 1

Conditions

Rectal Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 28Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4Capecitabine 4olaparib 3copper dotatate CU-64 3atezolizumab 3Temozolomide 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endoscopic Mucosal Resection × NET × 1 year × Clear all
NCT07612748 2026-06-03

Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms

Jilin University

Phase NA Recruiting
483 enrolled
EndocrineGastrointestinalNET

Rectal Neuroendocrine Tumors

NCT07373015 2026-01-28

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase NA Not yet recruiting
118 enrolled
EndocrineGastrointestinalNET

Rectal Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡